Meridian Bioscience receives U.S. FDA Emergency Use Authorization for Revogene SARS-CoV-2 molecular assay
The company expects to begin shipping this product before the end of its fiscal first quarter, ending December 31, 2021
The company expects to begin shipping this product before the end of its fiscal first quarter, ending December 31, 2021
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
Subscribe To Our Newsletter & Stay Updated